Continuing Essential Cancer Treatment While Maximizing Protection of the Heart
The cardio-oncology program at Smilow Cancer Hospital at Yale-New Haven is a combined inpatient and outpatient consultative service that addresses the cardiovascular complications of cancer and its treatment.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
2 Clarke Drive Cranbury, NJ 08512